Announcements Trials
Browse Landscape

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 71Neoplasm Metastasis 11Brain Neoplasms 7Triple Negative Breast Neoplasms 5Stomach Neoplasms 3Neoplasms 3HER2-positive Breast Cancer 3Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 2Breast Cancer With Brain Metastasis 2Advanced Breast Cancer 2Unresectable Locally Recurrent Breast Cancer 1Salivary Gland Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm, Residual 1Meningeal Carcinomatosis 1Inflammatory Breast Neoplasms 1HER2-negative Breast Cancer 1HER2-low Hormone Receptor Positive Breast Cancer 1HER2-Positive Primary Breast Cancer 1HER2 Overexpression 1Glioma 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Drug-Related Side Effects and Adverse Reactions 1Colonic Neoplasms 1Carcinosarcoma 1Carcinoma, Transitional Cell 1

Interventions

trastuzumab deruxtecan 1Isovaleryl-CoA Dehydrogenase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
HER2 Overexpression × trastuzumab deruxtecan × Breast × Clear all
NCT07035353 2025-06-25

A Real-world Clinical Study of T-DXd for the Treatment of Chinese Patients With HER2 Overexpressing and HER2 Underexpressing Advanced Breast Cancer

Tianjin Medical University Cancer Institute and Hospital

Not yet recruiting
200 enrolled
Breast

HER2 Overexpression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡